Showing results (11-20 of 81) with videos related to
Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 30, 2003
Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high?Gary E Stein, Sharon Schooley, Glenn W KaatzAntimicrobial Agents and Chemotherapy|April 28, 2005
Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport proteinGlenn W Kaatz, Fionnuala McAleese, Susan M SeoBioorganic & Medicinal Chemistry Letters|February 5, 2008
Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumpsNadezhda German, Glenn W Kaatz, Robert J KernsBioorganic & Medicinal Chemistry Letters|May 20, 2004
Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumpsPeng Wei, Glenn W Kaatz, Robert J KernsFuture Microbiology|March 29, 2013
Inhibition of drug efflux pumps in Staphylococcus aureus: current status of potentiating existing antibioticsBryan D Schindler, Pauline Jacinto, Glenn W KaatzAntimicrobial Agents and Chemotherapy|December 24, 2004
Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporterGlenn W Kaatz, Rama V Thyagarajan, Susan M SeoAntimicrobial Agents and Chemotherapy|March 30, 2006
MepR, a repressor of the Staphylococcus aureus MATE family multidrug efflux pump MepA, is a substrate-responsive regulatory proteinGlenn W Kaatz, Carmen E DeMarco, Susan M SeoInternational Journal of Antimicrobial Agents|August 4, 2004
In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J RybakAntimicrobial Agents and Chemotherapy|July 25, 2003
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J RybakInternational Journal of Antimicrobial Agents|September 12, 2006
Mechanisms of daptomycin resistance in Staphylococcus aureusGlenn W Kaatz, Tammy S Lundstrom, Susan M SeoPageof 9